Neoplastic risk for liver and colon in primary sclerosing cholangitis

Abstract

Primary sclerosing cholangitis (PSC) is a rare disease that may well be notified as a premalignant condition due to the increased cancer risk. The risk is highest for hepatobiliary cancer and increased by 28-398 times compared to the general population. When comorbidity with inflammatory bowel disease exists, the risk for colorectal cancer is increased 5-12 times and may even be higher after liver transplantation. The cancer risk estimates have decreased with time but vary according to study design. More recent population-based studies have approximated lower cancer risk than previous studies. Higher awareness and earlier detection of PSC together with increased surveillance over time may have influenced risk estimates. Surveillance for PSC patients is recommended for early tumor detection in both the liver and colon to enable curative treatment. The evidence for the efficacy of surveillance for early detection of hepatobiliary cancer is weak and an accepted common strategy worldwide is lacking. The high risk of hepatobiliary cancers has been confirmed repeatedly and future studies in PSC should focus on individualizing follow-up strategies and treatment.

Keywords

Epidemiology / inflammatory bowel disease / hepatobiliary cancer / cholangiocarcinoma / gallbladder cancer / hepatocellular carcinoma / pancreatic cancer / colorectal cancer

References

[1] Boonstra K,van Erpecum KJ.EpiPSCPBC Study GroupPopulation-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.Hepatology2013;58:2045-55

[2] Barner-Rasmussen N,Jussila A.Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland.Scand J Gastroenterol2020;55:74-81

[3] Liang H,Shick J,Dolin P.Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom.Medicine (Baltimore)2017;96:e7116 PMCID:PMC5478316

[4] Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort.Liver Int2012;32:441-8

[5] Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World J Gastroenterol2015;21:1956-71 PMCID:PMC4323476

[6] Loftus EV Jr,Loftus CG.PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.Gut2005;54:91-6 PMCID:PMC1774346

[7] Jørgensen KK,Lundin KE.Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients.Inflamm Bowel Dis2012;18:536-45

[8] Rizvi S,Gores GJ.Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management.Clin Gastroenterol Hepatol2015;13:2152-65 PMCID:PMC4618039

[9] Folseraas T.Cancer risk and surveillance in primary sclerosing cholangitis.Clin Liver Dis2016;20:79-98

[10] Tischendorf JJ,Krüger M,Meier PN.Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study.Am J Gastroenterol2007;102:107-14

[11] Bergquist A,Olsson R.Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.J Hepatol2002;36:321-7

[12] Ananthakrishnan AN,Gainer VS.Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.J Crohns Colitis2014;8:956-63 PMCID:PMC4136996

[13] Trivedi PJ,Mytton J.Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age.Gastroenterology2020;159:915-28

[14] Takakura WR,Bowlus CL.The evolution of natural history of primary sclerosing cholangitis.Curr Opin Gastroenterol2017;33:71-7 PMCID:PMC5538137

[15] Gores GJ,Rosen CB.Cholangiocarcinoma: is transplantation an option?.J Hepatol2007;47:455-9

[16] Rosen CB,Gores GJ.Surgery for cholangiocarcinoma: the role of liver transplantation.HPB (Oxford)2008;10:186-9 PMCID:PMC2504373

[17] Björnsson E,Cullen S.Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis.Gut2002;51:731-5 PMCID:PMC1773443

[18] Floreani A,Ferrara F.Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.Am J Gastroenterol2005;100:1516-22

[19] Weismüller TJ,Bergquist A.International PSC Study GroupPatient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis.Gastroenterology2017;152:1975-84.e8 PMCID:PMC5546611

[20] Bowlus CL,Lindor KD.AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: expert review.Clin Gastroenterol Hepatol2019;17:2416-22

[21] Lundberg Båve A,von Seth.Cancer risk in primary sclerosing cholangitis.ueg journal2019;7:153

[22] Chapman RW.Are dominant strictures in primary sclerosing cholangitis a risk factor for cholangiocarcinoma?.Curr Hepatol Rep2017;16:124-9 PMCID:PMC5486581

[23] Rudolph G,Kloeters-Plachky P,Kulaksiz H.In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.J Hepatol2010;53:313-7

[24] Bergquist A,Persson B.Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.Hepatology1998;27:311-6

[25] Chalasani N,Ismail A.Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.Hepatology2000;31:7-11

[26] Broomé U,Veress B.Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.Hepatology1995;22:1404-8

[27] Gulamhusein AF,Tabibian JH,Juran BD.Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD.Am J Gastroenterol2016;111:705-11 PMCID:PMC5027894

[28] Broomé U,Lööf L.Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.Gut1996;38:610-5 PMCID:PMC1383124

[29] Ahrendt SA,Nakeeb A.Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.J Gastrointest Surg1999;3:357-67; discussion 367

[30] Chapman MH,Bannoo S,Wittmann J.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience.Eur J Gastroenterol Hepatol2012;24:1051-8 PMCID:PMC3584158

[31] Kornfeld D,Ihre T.Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.Scand J Gastroenterol1997;32:1042-5

[32] Bakhshi Z,Gores GJ.An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.J Gastroenterol2020;55:523-32 PMCID:PMC8157157

[33] Burak K,Pasha TM,Petz J.Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.Am J Gastroenterol2004;99:523-6

[34] Fevery J,Lai G,Van Steenbergen W.Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.Dig Dis Sci2007;52:3123-35

[35] Fevery J,Van Oirbeek R.Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study.Liver Int2012;32:214-22

[36] Said K,Bergquist A.Gallbladder disease in patients with primary sclerosing cholangitis.J Hepatol2008;48:598-605

[37] van Erp LW,Narasimman M.Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps.Liver Int2020;40:382-92

[38] Buckles DC,Larusso NF,Gores GJ.In primary sclerosing cholangitis, gallbladder polyps are frequently malignant.Am J Gastroenterol2002;97:1138-42

[39] Sagvand B, Edwards K, Shen B. Frequency, risk factors, and outcome of gallbladder polyps in patients with primary sclerosing cholangitis: a case-control study.Hepatol Commun2018;2:1440-5 PMCID:PMC6287476

[40] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[41] Harnois DM,Ludwig J,Larusso NF.Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?.J Hepatol1997;27:512-6

[42] Zenouzi R,Hübener P.Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.Clin Gastroenterol Hepatol2014;12:1733-8

[43] Ali AH,Nasser-Ghodsi N.Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.Hepatology2018;67:2338-51

[44] Everhov ÅH,Sachs MC.Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017.Aliment Pharmacol Ther2020;52:143-54

[45] Charatcharoenwitthaya P,Halling KC.Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.Hepatology2008;48:1106-17

[46] Razumilava N,Lindor KD.Cancer surveillance in patients with primary sclerosing cholangitis.Hepatology2011;54:1842-52 PMCID:PMC3205332

[47] Eaton JE,Bakhshi Z.Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.Hepatology2021;73:1868-81 PMCID:PMC8177077

[48] Boyd S,Jokelainen K.Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis.World J Gastroenterol2017;23:6147-54 PMCID:PMC5597506

[49] Andersen IM,Boberg KM.Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway.Transplant Direct2015;1:e39 PMCID:PMC4946487

[50] Majeed A,Arnelo U,Bergquist A.Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation.Scand J Gastroenterol2018;53:56-63

[51] Ramage JK,Farrant J,Williams R.Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Gastroenterology1995;108:865-9

[52] Hultcrantz R,Danielsson Å.A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.J Hepatol1999;30:669-73

[53] Sinakos E,Keach J,Lindor KD.Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.Clin Gastroenterol Hepatol2011;9:434-9.e1

[54] Venkatesh PG,Shen B.Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.Dig Dis Sci2013;58:850-7

[55] Levy C,Angulo P,Larusso N.The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.Dig Dis Sci2005;50:1734-40

[56] Wannhoff A,Knierim J,Rupp C.Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.Aliment Pharmacol Ther2019;49:769-78

[57] Wannhoff A,Folseraas T.FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.J Hepatol2013;59:1278-84

[58] Wannhoff A,Friedrich K.Inflammation but not biliary obstruction is associated with carbohydrate antigen 19-9 levels in patients with primary sclerosing cholangitis.Clin Gastroenterol Hepatol2015;13:2372-9

[59] Wiles R,Barbu ST.Management and follow-up of gallbladder polyps : joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE).Eur Radiol2017;27:3856-66 PMCID:PMC5544788

[60] Lindor KD,Harrison ME.American College of GastroenterologyACG clinical guideline: primary sclerosing cholangitis.Am J Gastroenterol2015;110:646-59; quiz 660

[61] Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases.J Hepatol2009;51:237-67

[62] Krugliak Cleveland N,Hart J.Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon.Clin Gastroenterol Hepatol2018;16:68-74 PMCID:PMC5735030

[63] Ricciuto A,Carman N.Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis.Clin Gastroenterol Hepatol2018;16:1098-1105.e1

[64] Shah SC,Castaneda D.High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease.Clin Gastroenterol Hepatol2018;16:1106-1113.e3

[65] Soetikno RM,Heidenreich PA,Blackstone MO.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.Gastrointest Endosc2002;56:48-54

[66] Zheng HH.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.Eur J Gastroenterol Hepatol2016;28:383-90

[67] Kornfeld D,Ihre T.Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis?.Gut1997;41:522-5 PMCID:PMC1891549

[68] Sørensen JØ,Andersson M.Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977-2011.Liver Int2018;38:532-41

[69] Sharma P.Gastrointestinal dysplasia.Pathology2013;45:273-85

[70] Card TR,West J.Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study.J Hepatol2008;48:939-44

[71] Braden B,Aryasingha S.Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.Clin Gastroenterol Hepatol2012;10:303-8

[72] Lindström L,Ost A.Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis.Dis Colon Rectum2011;54:1392-7

[73] Navaneethan U,Venkatesh PG.Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn's colitis.Gastroenterol Rep (Oxf)2016;4:226-31 PMCID:PMC4976675

[74] Jess T,Velayos FS.Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.Am J Gastroenterol2007;102:829-36

[75] Shetty K,Brzezinski A,Lashner BA.The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis.Am J Gastroenterol1999;94:1643-9

[76] Lundqvist K.Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study.Dis Colon Rectum1997;40:451-6

[77] Moayyeri A,Bahrami H,Nayyer-Habibi A.Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis.J Gastroenterol Hepatol2005;20:366-70

[78] Barrasa JI,Lizarbe MA.Bile acids in the colon, from healthy to cytotoxic molecules.Toxicol In Vitro2013;27:964-77

[79] Sabino J,Machiels K.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.Gut2016;65:1681-9 PMCID:PMC5036217

[80] Dvorchik I,Demetris AJ.Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis.Hepatology2002;35:380-4 PMCID:PMC2965629

[81] Goss JA,Farmer DG.Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.Ann Surg1997;225:472-81; discussion 481 PMCID:PMC1190779

[82] Vera A,Ussatoff V.Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.Transplantation2003;75:1983-8

[83] Jørgensen KK,Cvancarova M.Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.Scand J Gastroenterol2012;47:1021-9

[84] Singh S,Loftus EV Jr.Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis.Liver Transpl2013;19:1361-9

[85] Lutgens M,Van Oijen M.Dutch Initiative on Crohn and ColitisA rule for determining risk of colorectal cancer in patients with inflammatory bowel disease.Clin Gastroenterol Hepatol2015;13:148-54.e1

[86] Hovde Ø,Henriksen M,Småstuen MC.Malignancies in patients with inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study.J Crohns Colitis2017;11:571-7

[87] Askling J,Karlén P.Family history as a risk factor for colorectal cancer in inflammatory bowel disease.Gastroenterology2001;120:1356-62

[88] Rutter MD,Wilkinson KH.Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.Gut2004;53:1813-6 PMCID:PMC1774334

[89] Rutter M,Wilkinson K.Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.Gastroenterology2004;126:451-9

[90] Velayos FS,Jess T.Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study.Gastroenterology2006;130:1941-9

[91] Gumaste V,Greenstein AJ.Benign and malignant colorectal strictures in ulcerative colitis.Gut1992;33:938-41 PMCID:PMC1379408

[92] Magro F,Eliakim R.European Crohn’s and Colitis Organisation [ECCO]Third European evidence-based consensus on diagnosis and management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders.J Crohns Colitis2017;11:649-70

[93] Bhat P.Role of endoscopy in primary sclerosing cholangitis.Clin Endosc2021;54:193-201 PMCID:PMC8039754

[94] Society of Gastrointestinal Endoscopy; European Association for the Study of the Liver; Electronic address: [e-mail]; European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European society of Gastrointestinal Endoscopy (ESGE) and European Association for the study of the Liver (EASL) clinical guideline.J Hepatol2017;66:1265-81

[95] Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases.J Hepatol2009;51:237-67

[96] Chapman MH,Hirschfield GM.British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.Gut2019;68:1356-78 PMCID:PMC6691863

[97] Saffioti F,Hawkins N.Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.Cochrane Database Syst Rev2017;3:CD011343 PMCID:PMC6464655

[98] Choi J,Peeraphatdit T.Aspirin use and the risk of cholangiocarcinoma.Hepatology2016;64:785-96 PMCID:PMC5995727

[99] Altaii H,Oliveira GH,Romero-Marrero C.Aspirin use and risk of cholangiocarcinoma: external validation with big data.Hepatology2017;65:1421-2

[100] Rothwell PM,Elwin C.Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.Lancet2010;376:1741-50

[101] Jackson SS,Liu Z.Association between aspirin use and biliary tract cancer survival.JAMA Oncol2019;5:1802-4 PMCID:PMC6802421

[102] Restivo A,Casula G.Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer.Br J Cancer2015;113:1133-9 PMCID:PMC4647877

[103] Abushamma S.Aspirin and statin use in preventing cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC): 866.Am J Gastroenterol2018;113:S482-3

[104] Bonovas S,Flordellis CS.Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients.J Clin Oncol2007;25:3462-8

[105] Bonilla LM,Harmsen W.3437 Associations of aspirin, non-aspirin NSAIDs, statins, and metformin with risk of biliary cancer: a Swedish population-based cohort study.J Clin Trans Sci2019;3:35-35

[106] Liu Z,McGlynn KA.Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink.Gut2019;68:1458-64 PMCID:PMC6525087

[107] Lavu S,Harmsen WS.Effect of statins on the risk of extrahepatic cholangiocarcinoma.Hepatology2020;72:1298-309 PMCID:PMC8155698

[108] Bonovas S,Lytras T,Peyrin-Biroulet L.Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.Aliment Pharmacol Ther2017;45:1179-92

[109] OʼConnor A,Akbari M.Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis.Inflamm Bowel Dis2015;21:2562-9

[110] Zhao LN,Yu T,Yuan YH.5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis.PLoS One2014;9:e94208 PMCID:PMC3978022

[111] Nguyen GC,Bernstein CN.5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations.Am J Gastroenterol2012;107:1298-304; quiz 1297, 1305

[112] Jess T,Andersson M,Peyrin-Biroulet L.Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis.Clin Gastroenterol Hepatol2014;12:1793-1800.e1

[113] Terdiman JP,Blumentals WA,Rubin DT.5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.Inflamm Bowel Dis2007;13:367-71

[114] Tung BY,Haggitt RC.Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Ann Intern Med2001;134:89-95

[115] Pardi DS,Kremers WK,Lindor KD.Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.Gastroenterology2003;124:889-93

[116] Lindström L,Wikman O.High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.Aliment Pharmacol Ther2012;35:451-7

[117] Wolf JM,Lashner BA.The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.Aliment Pharmacol Ther2005;22:783-8

[118] Singh S,Pardi DS,Talwalkar JA.Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.Inflamm Bowel Dis2013;19:1631-8

[119] Eaton JE,Pardi DS.High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.Am J Gastroenterol2011;106:1638-45 PMCID:PMC3168684

[120] Lapitz A,O'Rourke CJ.Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis.Cells2020;9:721 PMCID:PMC7140677

[121] Loosen SH,Wiltberger G.Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma.PLoS One2019;14:e0210944 PMCID:PMC6336320

[122] Wannhoff A.Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis.Clin Res Hepatol Gastroenterol2019;43:236-43

[123] Singhi AD,Chennat J.Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures.Gut2020;69:52-61 PMCID:PMC6943248

[124] Boberg KM,Mitchell S.Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.Scand J Gastroenterol2002;37:1205-11

[125] Morris-Stiff G,Olliff S.Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience.Dig Surg2008;25:126-32

[126] Claessen MM,Tytgat KM,van Buuren HR.High lifetime risk of cancer in primary sclerosing cholangitis.J Hepatol2009;50:158-64

[127] McGee EE,Engels EA.Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.Int J Cancer2019;144:707-17

[128] Wiesner RH,Dickson ER.Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.Hepatology1989;10:430-6

[129] Farrant J,Wilkinson ML.Natural history and prognostic variables in primary sclerosing cholangitis.Gastroenterology1991;100:1710-7

[130] Nashan B,Tusch G.Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation.Hepatology1996;23:1105-11

[131] Jess T,Jørgensen KT,Nielsen NM.Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.Gastroenterology2012;143:375-81.e1; quiz e13

[132] Guerra I,Castro J.Spanish GETECCU group (ENEIDA Project)Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study.J Crohns Colitis2019;13:1492-500

[133] Sokol H,Chazouilleres O.Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.World J Gastroenterol2008;14:3497-503 PMCID:PMC2716611

[134] Terg R,Coronel E.Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study.Acta Gastroenterol Latinoam2008;38:26-33